The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1599
ISSUE1599
June 1, 2020
Eptinezumab (Vyepti) for Migraine Prevention
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Eptinezumab (Vyepti) for Migraine Prevention
June 1, 2020 (Issue: 1599)
The FDA has approved eptinezumab-jjmr (Vyepti –
Lundbeck), a calcitonin gene-related peptide (CGRP)
antagonist administered IV once every 3 months, for
migraine prevention in adults. It is the fourth monoclonal
antibody to be approved for this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.